Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by The Bioverge Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Bioverge Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Developing Next-Generation Small Molecule Drugs

49:36
 
Share
 

Manage episode 351244397 series 2874357
Content provided by The Bioverge Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Bioverge Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Ramsey Homsany, co-founder and president of Octant Bio, sits down with Neil to discuss the company’s efforts to tackle complex diseases with next-generation small molecule drugs by harnessing synthetic biology to better understand the biochemical mechanisms of its targets, his unusual path to leadership of a biotechnology company, and Octant’s collaboration with Bristol Myers Squibb to apply its platform technologies to a set of inflammation-related pathways.
  continue reading

43 episodes

Artwork
iconShare
 
Manage episode 351244397 series 2874357
Content provided by The Bioverge Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Bioverge Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Ramsey Homsany, co-founder and president of Octant Bio, sits down with Neil to discuss the company’s efforts to tackle complex diseases with next-generation small molecule drugs by harnessing synthetic biology to better understand the biochemical mechanisms of its targets, his unusual path to leadership of a biotechnology company, and Octant’s collaboration with Bristol Myers Squibb to apply its platform technologies to a set of inflammation-related pathways.
  continue reading

43 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play